Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Association of Human Endogenous Retrovirus K (HERV-K) Expression with Prostate Cancer Development and Progression

Principal Investigator
Name
Stefan Ambs
Degrees
-
Institution
-
Position Title
-
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2009-0552
Initial CDAS Request Approval
Dec 15, 2009
Title
Association of Human Endogenous Retrovirus K (HERV-K) Expression with Prostate Cancer Development and Progression
Summary
Research in our laboratory discovered a distinct gene signature in prostate tumors of African-American patients consistent with either a viral infection or reactivation of endogenous retroviruses in the tumor microenvironment 1. Human endogenous retroviral sequences (HERVs) comprise ~8% of our genome 2. Their reactivation has been observed in several human cancers 3-5. Of all known HERVs, HERV-K is the most intact and transcriptionally active endogenous retrovirus and can trigger an immune response 2,3,6. Expression differences for HERV-K amongst ethnic groups have been described, with some polymorphic HERV-K sequences being most frequently expressed in African populations 7. Given the association of HERV-K with human cancer and expression differences by ancestry, we investigated the association of HERV-K expression with prostate cancer in European-American and African-American men. In a pilot case-control study, HERV-K expression was evaluated from buffy coat in 294 prostate cancer cases and 135 population-based controls. This study found HERV-K to be significantly associated with prostate cancer in a dose-dependent manner among both African-American and European-American men. Furthermore, African-American controls had significantly higher HERV-K expression than European-American controls. The data suggest that HERV-K expression could be an unrecognized and significant pre-disposing factor in prostate cancer, or a disease effect. Because pre-diagnostic samples were not available in the pilot, we could not determine whether HERV-K expression precedes disease development. In any case, the findings from the pilot are novel and significant, and should be pursued in a larger setting. In this proposal, we aim to validate the association of HERV-K with prostate cancer. Moreover, we propose to investigate pre-diagnostic samples to determine if reactivation of HERV-K is a risk factor and marker of prostate cancer that precedes diagnosis. Finally, we propose to analyze HERV-K expression in early and advanced prostate cancer to examine whether the HERV-K burden increases with disease progression.
Aims

Primary Hypothesis: HERV-K expression in buffy coat is associated with prostate cancer development and progression in African-American (AA) and European-American (EA) men. Specific Aim 1: Examine the association between HERV-K expression and prostate cancer development in a) all men, b) EA men and c) AA men in PLCO using a nested case control design. Specific Aim 2: Examine whether HERV-K expression is a pre-diagnostic marker for prostate cancer. Specific Aim 3: Examine HERV-K expression in non-advanced versus advanced stage disease

Collaborators

Amanda Black (NCI, DCEG)
Paul Pinsky (NCI, DCEG)
Tiffany Wallace (NCI, CCR)
Stefan Ambs (NCI, CCR) - Current Lead Investigator (3/4/2013)

Related Publications